New Market Report Now Available: Canada Pharmaceuticals & Healthcare Report Q2 2011

April 25, 2011 - PRLog -- The primary threat to the Canadian economy in 2011-12 is the increasingly stretched state of household balance sheets, which will keep both private consumption and residential construction growth relatively muted for the next couple of years. With a sharper-than-expected slowdown in H210, and a 1.0% quarter-on-quarter (q-o-q) annualised growth reading in Q310, we have lowered our real GDP growth estimate for 2010 as a whole from 3.1% to 2.9%. However, our 2011 forecast of 2.4% remains unchanged, and we are still forecasting a solid 3.0% rate of growth in 2012. Our view is that Canadian growth is rebalancing - moving away from private consumption, and towards domestic business investment and production.

In BMI's Business Environment Ratings for Q211, Canada remains in second place in the expanded regional matrix on a global scale, Canada also ranks second of the 83 markets surveyed globally, behind the US and above Japan. The new ratings criteria serve to reinforce our estimation of the country's potential, owing to a stronger emphasis on regulatory factors, which we see as a major feature affecting the business environment for drugmakers. However, cost-containment pressures, both at a federal and provincial level, will continue to pose an issue to manufacturers of novel products.

The country's healthcare system is increasingly being recognised as inadequate and cannot meet the long-term needs of the population. Consequently, extensive reforms are being proposed ahead of the renegotiation of the current Health Accord, which is set to expire on March 31 2014. Over the past five years, pharmaceutical sales growth has slowed significantly as the government has attempted to control runaway healthcare spending. Market growth should be limited in the short and medium term. In the face of increased drug expenditure, government cost-cutting measures are set to gain pace and the substitution of patented drugs with generic drugs will accelerate.

BMI expects the prescription drug market to increase from US$21.38bn in 2010 to US$23.04bn by 2015. By 2020, the prescription drug market will be worth US$28.22bn and will account for 86.6% of the total pharmaceutical market, up from 86.2% in 2010. Five- and ten-year CAGRs in local currency terms are expected to come in at 3.61 and 3.87%, respectively. The OTC market will increase in value from US$3.42bn in 2010 to US$3.61bn by 2015, at a CAGR of 1.09% in US dollars and 3.14% in local currency. OTC drugs will comprise 13.56% of the total pharmaceutical market by 2015 and 13.35% by 2020, a decline from the 13.8% calculated in 2010.

Presently, generic drug uptake in Canada is significantly less than the uptake of patented medicines. This is largely down to several factors. Firstly, the price of generic drugs is not significantly cheaper than their patented counterparts. Patented drugs have a regulatory approval board which has some influence over pricing; however there is no equivalent in place for generics. Drug pricing is generally allocated by province or territory, which can cause further discrepancies between medicines in difference areas. Generic drug prescribing practices are still need to be encouraged, especially at a time when public healthcare and access to medicines is a matter of public interest.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/149596_canada_pharmaceuticals_...


Partial Table of Contents:

SWOT Analysis
- Canada Pharmaceuticals And Healthcare Industry SWOT
- Canada Political SWOT
- Canada Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Americas - Pharmaceuticals Business Environment Ratings, Q211
- Risks
Canada - Market Summary
Regulatory Regime
- Pharmacovigilance
- Biosimilars
- OTC Medicines
- International Collaboration
Intellectual Property Regime
Pricing Regime
- Provincial Pricing Systems
- Reimbursement Regime
- Recent Pricing and Reimbursement Developments
Industry Developments
- Epidemiology
- Healthcare Sector
- International Comparison
- Health Expenditure
- Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators
- National Pharmaceuticals Strategy
- Pharmaceutical Retail
- Research and Development Sector
- Biotechnology
- Medical Devices Industry
- Recent Developments in the Medical Devices Industry
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Canada - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports Indicators 2007-2015
- Table: Imports Indicators 2007-2015
- Other Healthcare Data
Competitive Landscape
- Pharmaceutical Industry
- Pharmaceutical Re-import Policy
- Recent Pharmaceutical Company Developments
- Top 20 Pharmaceutical Companies According To Market Capitalisation On The Canadian Stock Exchange
Company Profiles
- Domestic Manufacturers
- Apotex

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1495...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.